Therefore, the therapeutic application of STING agonists in the context of liver disease, particularly during the progression from chronic liver disease to HCC, requires careful consideration and a thorough understanding of its context-dependent effects. This evidence concerns the gene STING1 and hepatocellular carcinoma.